Abstract
Unusually small intravenous doses of amphotericin B (10 to 355 mg given over 4 to 18 days) were effective in the treatment of 14 selected patients with severe and disabling<i>Candida</i>infections. These included nine with mucocutaneous infections in whom vigorous topical antifungal therapy had failed. Five other patients had systemic disease that had not responded to the removal of intravenous catheters or discontinuation of antibiotics. Follow-up over 2 to 24 months showed no recurrences. No toxicity was encountered except in the recipient of the largest dose, who had transient azotemia. Our limited experience suggests the efficacy of amphotericin B in small nontoxic doses in the treatment of mucocutaneous and systemic<i>Candida</i>infections, excluding meningitis and endocarditis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
